Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, May 5, 2022 - Addex Therapeutics (SIX:ADXN and Nasdaq:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the quarter ended March 31, 2022. A full corporate update will be provided with the release of data from the Phase 2 clinical study of dipraglurant in blepharospasm, expected during the second quarter of 2022.
Read more at globenewswire.com